Vertex Pharmaceuticals (VRTX)

They trade at some incredibly low earnings multiples.

Vertex Pharmaceuticals (VRTX) is a top growth stock with strong fundamentals, high profitability, and a technical setup hinting at a potential breakout for investors.

These companies are reaching key milestones.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Recent developments aren't as devastating to the company's prospects as some might think.

Vertex Pharmaceuticals (VRTX) exemplifies the GARP strategy with strong growth, a reasonable valuation, high profitability, and a robust debt-free balance sheet.

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

Investing in these pharmaceutical stocks is an easy decision.

Looking for good investing ideas? These two stocks could be huge winners for long-term investors.

Vertex Pharmaceuticals (VRTX) is a top value stock with strong financials, high profitability, and impressive growth, trading below its biotech peers.

The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty, the underlying currents suggest continued, albeit slower, economic expansion, particularly within the United States. Investors are keenly watching the interplay

It's been an unusually bad year for this drugmaker, but it's essential to look beyond that.

These stocks should be able to rebound strongly.

Shares of the pharma company are down 17% in the past 12 months.

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.

Palantir leads all stocks in the S&P 500 with a stunning 160% gain in Trump's first 200 days.

This biotech's innovative approach could pay rich dividends down the road.

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive entry point.

These stocks have outperformed broader equities over the past decade and still have room to run.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.